LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Kodu・Aktsiate loetelu・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

36.86 1.01

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.65

Max

37.47

Põhinäitajad
By Trading Economics
Sissetulek	7.3M -123M
Müük	3.7M 3.9M
Aktsiakasum	-1.29
Kasumimarginaal	-3,161.261
Töötajad	594
EBITDA	20M -122M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+134.61% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-140M 4.3B
Eelmine avamishind	35.85
Eelmine sulgemishind	36.86

Uudiste sentiment

By Acuity

58%

42%

280 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

30.39 / 33.46 Toetus ja vastupanu

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. mai 2026, 22:50 UTC

Tulu

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12. mai 2026, 22:49 UTC

Tulu

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12. mai 2026, 22:32 UTC

Tulu

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12. mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12. mai 2026, 22:57 UTC

Market Talk

Tulu

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12. mai 2026, 22:26 UTC

Tulu

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12. mai 2026, 22:25 UTC

Tulu

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12. mai 2026, 22:25 UTC

Tulu

Aristocrat Leisure Interim Dividend A$0.50/Security

12. mai 2026, 22:24 UTC

Tulu

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12. mai 2026, 22:23 UTC

Tulu

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12. mai 2026, 22:23 UTC

Tulu

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12. mai 2026, 22:19 UTC

Tulu

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12. mai 2026, 22:14 UTC

Tulu

CBA: Business Lending Continued to Grow Above System>CBA.AU

12. mai 2026, 22:14 UTC

Tulu

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12. mai 2026, 22:13 UTC

Tulu

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12. mai 2026, 22:12 UTC

Tulu

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12. mai 2026, 22:12 UTC

Tulu

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12. mai 2026, 22:11 UTC

Tulu

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12. mai 2026, 22:11 UTC

Tulu

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12. mai 2026, 22:10 UTC

Tulu

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12. mai 2026, 22:09 UTC

Tulu

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12. mai 2026, 22:09 UTC

Tulu

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12. mai 2026, 22:08 UTC

Tulu

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12. mai 2026, 22:07 UTC

Tulu

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12. mai 2026, 22:06 UTC

Tulu

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12. mai 2026, 22:06 UTC

Tulu

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12. mai 2026, 22:05 UTC

Tulu

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

134.61% tõus

12 kuu keskmine prognoos

Keskmine 85.75 USD 134.61%

Kõrge 97 USD

Madal 67 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Crinetics Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

30.39 / 33.46Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

280 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.